Published in Future Virol on July 01, 2010
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med (2000) 23.10
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet (2006) 11.06
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis (2005) 9.23
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
The health and health system of South Africa: historical roots of current public health challenges. Lancet (2009) 7.76
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis (2006) 7.42
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
Community-based approaches to HIV treatment in resource-poor settings. Lancet (2001) 7.13
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med (1997) 7.11
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA (2004) 7.04
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health (2001) 6.29
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health (2002) 6.01
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet (2008) 5.93
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS (2001) 5.61
Scaling up antiretroviral treatment in resource-poor settings. Lancet (2006) 5.51
Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr (2005) 4.96
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis (2006) 4.67
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis (2004) 4.17
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS (2010) 4.05
Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes--the case of Malawi. Int J Tuberc Lung Dis (2005) 4.04
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther (2008) 4.00
Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis (2002) 3.58
HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS (2008) 3.52
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
The real challenges for scaling up ART in sub-Saharan Africa. AIDS (2006) 3.02
A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis (2006) 2.88
Expanding access to antiretroviral therapy in sub-saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities. Am J Public Health (2005) 2.87
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS (2008) 2.85
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61
AIDS in America--forgotten but not gone. N Engl J Med (2010) 2.56
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
Are laboratory services coming of age in sub-Saharan Africa? Clin Infect Dis (2005) 2.46
Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bull World Health Organ (2007) 2.17
Hit HIV-1 hard, but only when necessary. Lancet (2000) 1.98
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med (2006) 1.97
AIDS and public policy: the lessons and challenges of "success" in Thailand. Health Policy (2003) 1.94
A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr (2008) 1.81
The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol (2005) 1.76
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med (1994) 1.72
Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières. AIDS (2003) 1.69
The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther (2007) 1.68
Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis (2009) 1.64
When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med (2003) 1.63
Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr (2006) 1.62
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis (2010) 1.55
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS (2007) 1.53
Can antiretroviral therapy eliminate HIV transmission? Lancet (2008) 1.53
When to start antiretroviral therapy? Clin Infect Dis (2008) 1.52
Secondary prevention of HIV infection: the current state of prevention for positives. Curr Opin HIV AIDS (2009) 1.46
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis (2006) 1.42
Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis (2008) 1.41
Different delivery models for antiretroviral therapy in sub-Saharan Africa in the context of 'universal access'. Trans R Soc Trop Med Hyg (2008) 1.40
Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr (2008) 1.36
'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. AIDS (2008) 1.35
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis (2002) 1.33
Combining prevention, treatment and care: lessons from South Africa. AIDS (2007) 1.31
Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther (2004) 1.30
Antiretroviral therapy where resources are limited. N Engl J Med (2003) 1.27
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS (2008) 1.26
HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS (2008) 1.24
Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses (2005) 1.24
HIV/AIDS. The great funding surge. Science (2008) 1.11
Civil society, political mobilization, and the impact of HIV scale-up on health systems in Brazil. J Acquir Immune Defic Syndr (2009) 0.92
Risk of HIV transmission in discordant couples. Lancet (2008) 0.88
Initiating therapy: when to start, what to use. J Infect Dis (2008) 0.82
The use of highly active retroviral therapy to reduce HIV incidence at the population level. CMAJ (2008) 0.80
Scientists explore use of anti-HIV drugs as a means to slow HIV transmission. JAMA (2010) 0.76
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (2009) 5.48
Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med (2008) 5.13
Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis (2005) 4.96
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA (2008) 3.61
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
Men who have sex with men: perceptions about sexual risk, HIV and sexually transmitted disease testing, and provider communication. Sex Transm Dis (2007) 3.51
A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol (2009) 3.26
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One (2012) 2.97
Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS (2005) 2.92
Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. PLoS One (2012) 2.82
A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70
Modelling the impact of migration on the HIV epidemic in South Africa. AIDS (2007) 2.63
AIDS in America--forgotten but not gone. N Engl J Med (2010) 2.56
Changes in risk behavior among HIV-positive patients during their first year of antiretroviral therapy in Cape Town South Africa. AIDS Behav (2008) 2.45
Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis (2002) 2.39
Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One (2013) 2.32
Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr (2006) 2.30
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med (2012) 2.19
HIV and STD status among MSM and attitudes about Internet partner notification for STD exposure. Sex Transm Dis (2008) 2.18
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17
Childhood sexual abuse is highly associated with HIV risk-taking behavior and infection among MSM in the EXPLORE Study. J Acquir Immune Defic Syndr (2009) 2.17
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS (2009) 2.12
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) (2003) 2.03
HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav (2014) 2.00
Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr (2004) 1.97
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis (2005) 1.95
The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS (2014) 1.94
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS (2012) 1.86
Unseen and unheard: predictors of sexual risk behavior and HIV infection among men who have sex with men in Chennai, India. AIDS Educ Prev (2009) 1.83
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
Sexual mixing patterns and partner characteristics of black MSM in Massachusetts at increased risk for HIV infection and transmission. J Urban Health (2009) 1.79
Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis (2001) 1.79
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Bisexuality, sexual risk taking, and HIV prevalence among men who have sex with men accessing voluntary counseling and testing services in Mumbai, India. J Acquir Immune Defic Syndr (2010) 1.76
HIV/AIDS and the Black Church: what are the barriers to prevention services? J Natl Med Assoc (2005) 1.74
ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care (2005) 1.73
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73
Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr (2002) 1.71
Health system and personal barriers resulting in decreased utilization of HIV and STD testing services among at-risk black men who have sex with men in Massachusetts. AIDS Patient Care STDS (2009) 1.69
Who gets tested for HIV in a South African urban township? Implications for test and treat and gender-based prevention interventions. J Acquir Immune Defic Syndr (2011) 1.67
HIV in Indian MSM: reasons for a concentrated epidemic & strategies for prevention. Indian J Med Res (2011) 1.67
The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One (2011) 1.67
Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. Clin Infect Dis (2013) 1.64
Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS (2011) 1.63
Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis (2007) 1.63
The failure of routine rapid HIV testing: a case study of improving low sensitivity in the field. BMC Health Serv Res (2010) 1.61
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS (2011) 1.60
High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol (2007) 1.60
Depressive symptoms, utilization of mental health care, substance use and sexual risk among young men who have sex with men in EXPLORE: implications for age-specific interventions. AIDS Behav (2008) 1.59
A survey of MSM HIV prevention outreach workers in Chennai, India. AIDS Educ Prev (2006) 1.58
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS (2012) 1.56
Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis (2007) 1.56
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis (2010) 1.55
Prospective associations between HIV-related stigma, transmission risk behaviors, and adverse mental health outcomes in men who have sex with men. Ann Behav Med (2011) 1.55
Emergency department patient acceptance of opt-in, universal, rapid HIV screening. Public Health Rep (2009) 1.54
Contact with HIV prevention programmes & willingness for new interventions among truckers in India. Indian J Med Res (2013) 1.51
Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS (2006) 1.51
Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst (2005) 1.50
Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS (2012) 1.48
HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis (2012) 1.47
Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis (2010) 1.46
The emerging HIV epidemic among men who have sex with men in Tamil Nadu, India: geographic diffusion and bisexual concurrency. AIDS Behav (2010) 1.43
Clinical profile of HIV in India. Indian J Med Res (2005) 1.41
Resilience as a research framework and as a cornerstone of prevention research for gay and bisexual men: theory and evidence. AIDS Behav (2014) 1.41
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt) (2008) 1.40
Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother (2006) 1.40
Perspectives on new recommendations for nonoccupational HIV postexposure prophylaxis. JAMA (2005) 1.39
Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis (2002) 1.38
Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods (2009) 1.38
Low perceived risk and high HIV prevalence among a predominantly African American population participating in Philadelphia's Rapid HIV testing program. AIDS Patient Care STDS (2011) 1.38
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Lack of understanding of acute HIV infection among newly-infected persons-implications for prevention and public health: The NIMH Multisite Acute HIV Infection Study: II. AIDS Behav (2009) 1.37
HIV superinfection in the era of increased sexual risk-taking. Sex Transm Dis (2004) 1.37
Ageing with HIV in South Africa. AIDS (2011) 1.37
Acceptability of an internet-based partner notification system for sexually transmitted infection exposure among men who have sex with men. Am J Public Health (2007) 1.37
Clinically significant depressive symptoms as a risk factor for HIV infection among black MSM in Massachusetts. AIDS Behav (2009) 1.35
Street workers and internet escorts: contextual and psychosocial factors surrounding HIV risk behavior among men who engage in sex work with other men. J Urban Health (2008) 1.35
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS (2014) 1.34
Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS (2010) 1.34
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. Sex Transm Dis (2009) 1.32
HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses (2005) 1.31
Testing a social-cognitive model of HIV transmission risk behaviors in HIV-infected MSM with and without depression. Health Psychol (2010) 1.31
Sexual behaviors of individuals with HIV living in South India: a qualitative study. AIDS Educ Prev (2007) 1.31
Initial commitment to pre-exposure prophylaxis and circumcision for HIV prevention amongst Indian truck drivers. PLoS One (2010) 1.31
Depressive symptoms and human immunodeficiency virus risk behavior among men who have sex with men in Chennai, India. Psychol Health Med (2009) 1.30
Suicidality, clinical depression, and anxiety disorders are highly prevalent in men who have sex with men in Mumbai, India: findings from a community-recruited sample. Psychol Health Med (2011) 1.29
Age-gaps in sexual partnerships: seeing beyond 'sugar daddies'. AIDS (2011) 1.29